Get notified when MLTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (new) — Putative class action filed Oct 2025 alleging Exchange Act violations related to allegedly false statements about Sonelokimab clinical benefits; amended complaint filed Apr 2026, motion to dismiss pending.
MLTX narrows net loss 10.3% to -$61.8M in Q2 2026 on positive Phase 3 data, $234M equity raise
Filed August 10, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read
Key Changes
-
high
Announced positive week-52 VELA-1/2 HS data (67.2% HiSCR75, 33.1% HiSCR100) and week-16 IZAR-1 PsA data (42.1% ACR50), supporting BLA submission end-Q3 2026 and H2 2027 U.S. launch.
MD&A: Clinical Milestones verify on EDGAR → -
high
Raised $234M net via June 2026 public offering ($189.8M), ATM sales ($44.3M in Q2), and drew $25M Tranche 2 debt
Notes: Financing Activities verify on EDGAR → -
high
Pharmaceutical tariffs of up to 100% on certain imports (patented drugs, APIs) authorized to begin July 31, 2026; substantial uncertainty on implementation, exemptions, and retaliatory actions.
Risk Factors: Tariffs verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FGBI 10-Q) is open in full — no account needed.
Partner
Trade MLTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 18, 2026 · How we verify